USPTO serial 76431735
ANTEVAS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MCMORROW, RONALD G
- Law office
- INTENT TO USE UNIT
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ANTEVAS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.)
Tokyo, JP
Other trademarks owned by Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.)
Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.)
Tokyo, JP
Other trademarks owned by Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.)
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
MARSHA G. GENTNER
MARSHA G GENTNER JACOBSON HOLMANPLLCTHE JENIFER BLDG400 SEVENTH ST N WWASHINGTON, DC 20004-2201Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | PHARMACEUTICAL PREPARATIONS, NAMELY ANTI-NEURODEGENERATIVE DRUGS, DRUGS FOR TREATING CEREBROVASCULAR AND PERIPHERAL VASCULAR DISEASES, ORGAN TRANSPLANT PROTECTANTS, ANTI-ULCER AND ANTI-CANCER DRUGS | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.)
- Other trademarks owned by Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.)
- Other trademarks in Class 005
- Similar marks named ANTEVAS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 1, 2005 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 1, 2005 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 21, 2004 | CFIT | CASE FILE IN TICRS | — |
| Mar 30, 2004 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 24, 2003 | PAPER RECEIVED | — | |
| Feb 24, 2003 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 28, 2003 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 8, 2003 | NPUB | NOTICE OF PUBLICATION | — |
| Nov 20, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 28, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 28, 2002 | PAPER RECEIVED | — | |
| Oct 17, 2002 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 15, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 23, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 23, 2002 | PAPER RECEIVED | — |